We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Steven Levine

Steven R. Levine MD, FAHA, FAAN, FANA

Professor of Neurology & Emergency Medicine; Vice Chair, Neurology; Chief of Neurology, University Hospital of Brooklyn; The State University of New York (SUNY) Health Science Center, Brooklyn, New York

Dr. Levine is a Professor of Neurology & Emergency Medicine and Vice Chairman of Neurology. Dr. Levine’s Clinical Research interests are in cerebrovascular disease and stroke. He was the Detroit area PI for the NIH-funded NINDS rt-PA Stroke Trial that led to FDA approval of the first treatment for acute ischemic stroke – tissue plasminogen activator (tPA). He has served as the Editor-in-Chief of the National Stroke Association’s Stroke-Clinical Updates and serves/served on the Editorial Boards of several peer-reviewed journals, including Neurology, Stroke, Future Neurology, Medicine, and Clinical Neuropharmacology. He serves as a consultant for NIH, AHA/ASA, NSA, and the pharmaceutical industry. Dr. Levine is local PI for 2 NINDS clinical trial networks (NETT, NeuroNEXT).

Disclosures

Disclosures: Steering Committee, PRISMS, a Genentech-funded randomized clinical trial of intravenous t-PA for minor stroke: modest honorarium and travel expenses